Pathogenic variants in the RET proto-oncogene cause multiple endocrine neoplasia type 2 (MEN2) and familial medullary thyroid cancer (FMTC); penetrance and clinical presentation varies according to the type and location of the variants. This evidence concerns the gene RET and multiple endocrine neoplasia type 2.